Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
Colorectal cancer is one of the most prevalent tumors and a leading cause of cancer-related mortality. Despite advances ...
Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses ...
In this global network study, researchers examined vitamin B12 levels as a possible biomarker for outcomes in colon cancer.
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
MedPage Today on MSN
Regimen improves PFS in highly mutated metastatic colorectal cancer
But is the combination a "viable alternative" to nivolumab and ipilimumab?
J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO conference.
Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...
Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal approaches.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results